IGF2BP3 has been reported to be upregulated in many types of tumors, including pancreatic cancer,33 lung adenocarcinoma,34 triple‐negative breast cancer,35 colorectal cancer,36 hepatocellular carcinoma,37 and gliomas,38 suggesting that IGF2BP3 can serve as a novel cancer biomarker for early diagnosis and prognosis. Here, IGF2BP3 is linked to familial pancreatic carcinoma.